StockNews.com started coverage on shares of Titan Pharmaceuticals (NASDAQ:TTNP – Free Report) in a report issued on Friday morning. The brokerage issued a sell rating on the specialty pharmaceutical company’s stock.
Titan Pharmaceuticals Price Performance
Shares of NASDAQ TTNP opened at $5.76 on Friday. The stock has a 50 day moving average price of $5.82 and a 200 day moving average price of $6.56. Titan Pharmaceuticals has a 52 week low of $4.24 and a 52 week high of $14.80.
Titan Pharmaceuticals (NASDAQ:TTNP – Get Free Report) last posted its quarterly earnings results on Thursday, August 15th. The specialty pharmaceutical company reported ($2.29) earnings per share (EPS) for the quarter.
Titan Pharmaceuticals Company Profile
Titan Pharmaceuticals, Inc, a pharmaceutical company, develops therapeutics for the treatment of chronic diseases in the United States and internationally. It develops products based on ProNeura, a proprietary long-term drug delivery platform. It also develops TP-2021 in combination with ProNeura technology for the treatment of chronic pruritus, a severe and debilitating condition defined as itching of the skin lasting longer than six weeks; and Nalmefene implant program for the prevention of opioid relapse following detoxification of patients suffering opioid use disorder.
Recommended Stories
- Five stocks we like better than Titan Pharmaceuticals
- 3 Stocks to Protect Your Portfolio from the Coronavirus Contagion
- Why Block’s Key Components Make It a Solid Investment Choice
- What is a Low P/E Ratio and What Does it Tell Investors?
- Is Applied Digital’s Stock Set to Surge With NVIDIA’s Backing?
- What Are Some of the Best Large-Cap Stocks to Buy?
- 4 Reasons to Consider Adding General Mills to Your Portfolio
Receive News & Ratings for Titan Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Titan Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
